Mark Scheideler is a renown expert in translational research. Mark founded HumanFirst Therapeutics. Several key career highlights include: Senior Scientific Officer at NIH; MD/SVP of R&D at MDS Proteomics, Head of Neurobiology Research at GSK, Program Head at Novo Nordisk.

Mark has a Ph.D. from University of Chicago, Duke University School of Medicine Research Fellow, B.A. Northwestern University